FDA approval expected for expanded use of Zevalin

09/4/2009 | Reuters

Analysts are expecting the FDA to approve the use of Spectrum Pharmaceuticals' cancer drug Zevalin as a first-line treatment for non-Hodgkin's lymphoma. The drug currently is approved as treatment for relapsed or refractory NHL. The FDA is set to hand down its decision on Monday.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX